title: Next science wound gel technology, a novel agent that inhibits biofilm development by gram-positive and gram-negative wound pathogens.
abstract: Loss of the skin barrier facilitates the colonization of underlying tissues with various bacteria, where they form biofilms that protect them from antibiotics and host responses. Such wounds then become chronically infected. Topical antimicrobials are a major component of chronic wound therapy, yet currently available topical antimicrobials vary in their effectiveness on biofilm-forming pathogens. In this study, we evaluated the efficacy of Next Science wound gel technology (NxtSc), a novel topical agent designed to kill planktonic bacteria, penetrate biofilms, and kill the bacteria within. In vitro quantitative analysis, using strains isolated from wounds, showed that NxtSc inhibited biofilm development by Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae by inhibiting bacterial growth. The gel formulation NxtSc-G5, when applied to biofilms preformed by these pathogens, reduced the numbers of bacteria present by 7 to 8 log10 CFU/disc or CFU/g. In vivo, NxtSc-G5 prevented biofilm formation for 72 h when applied at the time of wounding and infection and eliminated biofilm infection when applied 24 h after wounding and infection. Storage of NxtSc-G5 at room temperature for 9 months did not diminish its efficacy. These results establish that NxtSc is efficacious in vitro and in vivo in preventing infection and biofilm development by different wound pathogens when applied immediately and in eliminating biofilm infection already established by these pathogens. This novel antimicrobial agent, which is nontoxic and has a usefully long shelf life, shows promise as an effective agent for the prevention and treatment of biofilm-related infections.
authors.affiliation: Department of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
authors.forename: Kyle G
authors.initials: KG
authors.lastname: Miller
authors.affiliation: Department of Ophthalmology and Visual Sciences, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
authors.forename: Phat L
authors.initials: PL
authors.lastname: Tran
authors.affiliation: Department of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
authors.forename: Cecily L
authors.initials: CL
authors.lastname: Haley
authors.affiliation: Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
authors.forename: Cassandra
authors.initials: C
authors.lastname: Kruzek
authors.affiliation: Department of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA Department of Medical Education, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
authors.forename: Jane A
authors.initials: JA
authors.lastname: Colmer-Hamood
authors.affiliation: Next Science, Jacksonville, Florida, USA.
authors.forename: Matt
authors.initials: M
authors.lastname: Myntti
authors.affiliation: Department of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA abdul.hamood@ttuhsc.edu.
authors.forename: Abdul N
authors.initials: AN
authors.lastname: Hamood
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D040981:Acinetobacter baumannii / Q000187:drug effects; D000287:Administration, Topical; D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D005260:Female; D005782:Gels / Q000494:pharmacology; D007710:Klebsiella Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D007711:Klebsiella pneumoniae / Q000187:drug effects; D051379:Mice; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects; D014946:Wound Infection / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*
chemical_list: D000890:Anti-Infective Agents; D005782:Gels